Startup · $16m raised
Online casino platform offering slots and table games
Melbourne, VIC
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round OccuRx raised.
| Investor | Rounds | Invested |
|---|---|---|
| Uniseed | Unnamed stage | - |
| CUREator | Unnamed stage | $1,500,000 |
| Brandon BioCatalyst | Unnamed stage · Accelerator | $1,500,000 |
Investors whose own portfolio pages list OccuRx, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Stoic Venture Capital | its portfolio page ↗ |
The transaction that ended OccuRx's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| CERTA TherapeuticsTreatment of fibrotic diseases | Acquisition | 19 Dec 2024 | - | Brandon BioCatalyst, Brandon Capital |
Companies OccuRx acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Gareth Lewis | Chief Commercial Officer | Startup Daily, Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Dr Michelle Bradney | Chief Operating Officer | Startup Daily, Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Professor Darren Kelly | Executive Chair | Startup Daily, Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming OccuRx. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Certa Therapeutics has acquired OccuRx, combining two GPR68 fibrosis pipelines founded by Professor Darren Kelly, and says it will seek Series B funding to advance clinical development.
Australian biotech OccuRx secured $16 million co-led by Brandon BioCatalyst and Uniseed, including a CUREator grant, to advance its oral anti-fibrosis therapy into kidney disease trials; two executives also joined.
Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.
The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.